
FlÃ;vio Reis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8809446/publications.pdf

Version: 2024-02-01



FIÃ:WO REIS

#	Article	IF	CITATIONS
1	Beneficial Effects of Dietary Polyphenols on Gut Microbiota and Strategies to Improve Delivery Efficiency. Nutrients, 2019, 11, 2216.	4.1	268
2	Dexmedetomidine: Current Role in Anesthesia and Intensive Care. Revista Brasileira De Anestesiologia, 2012, 62, 118-133.	0.6	260
3	Regular physical exercise training assists in preventing type 2 diabetes development: focus on its antioxidant and anti-inflammatory properties. Cardiovascular Diabetology, 2011, 10, 12.	6.8	198
4	Effects of Sitagliptin Treatment on Dysmetabolism, Inflammation, and Oxidative Stress in an Animal Model of Type 2 Diabetes (ZDF Rat). Mediators of Inflammation, 2010, 2010, 1-11.	3.0	143
5	Diabetic Nephropathy Amelioration by a Low-Dose Sitagliptin in an Animal Model of Type 2 Diabetes (Zucker Diabetic Fatty Rat). Experimental Diabetes Research, 2011, 2011, 1-12.	3.8	128
6	Interleukin (IL)-22, IL-17, IL-23, IL-8, vascular endothelial growth factor and tumour necrosis factor-α levels in patients with psoriasis before, during and after psoralen-ultraviolet A and narrowband ultraviolet B therapy. British Journal of Dermatology, 2010, 163, 1282-1290.	1.5	120
7	ACE2 imbalance as a key player for the poor outcomes in COVID-19 patients with age-related comorbidities – Role of gut microbiota dysbiosis. Ageing Research Reviews, 2020, 62, 101123.	10.9	118
8	Câ€reactive protein and leucocyte activation in psoriasis <i>vulgaris</i> according to severity and therapy. Journal of the European Academy of Dermatology and Venereology, 2010, 24, 789-796.	2.4	107
9	Circulating adipokine levels in Portuguese patients with psoriasis <i>vulgaris</i> according to body mass index, severity and therapy. Journal of the European Academy of Dermatology and Venereology, 2010, 24, 1386-1394.	2.4	104
10	Diabetic gut microbiota dysbiosis as an inflammaging and immunosenescence condition that fosters progression of retinopathy and nephropathy. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 1876-1897.	3.8	102
11	Sitagliptin Prevents Inflammation and Apoptotic Cell Death in the Kidney of Type 2 Diabetic Animals. Mediators of Inflammation, 2014, 2014, 1-15.	3.0	97
12	Exercise training decreases proinflammatory profile in Zucker diabetic (type 2) fatty rats. Nutrition, 2009, 25, 330-339.	2.4	91
13	Spatial memory impairments in a prediabetic rat model. Neuroscience, 2013, 250, 565-577.	2.3	80
14	Regular Physical Exercise as a Strategy to Improve Antioxidant and Anti-Inflammatory Status: Benefits in Type 2 Diabetes Mellitus. Oxidative Medicine and Cellular Longevity, 2012, 2012, 1-15.	4.0	77
15	Therapeutic Options Targeting Oxidative Stress, Mitochondrial Dysfunction and Inflammation to Hinder the Progression of Vascular Complications of Diabetes. Frontiers in Physiology, 2018, 9, 1857.	2.8	75
16	Protective effects of the dipeptidyl peptidase IV inhibitor sitagliptin in the blood–retinal barrier in a type 2 diabetes animal model. Diabetes, Obesity and Metabolism, 2012, 14, 454-463.	4.4	74
17	Early cardiac changes in a rat model of prediabetes: brain natriuretic peptide overexpression seems to be the best marker. Cardiovascular Diabetology, 2013, 12, 44.	6.8	66
18	Characterization of solid lipid nanoparticles produced with carnauba wax for rosmarinic acid oral delivery. RSC Advances, 2015, 5, 22665-22673.	3.6	66

FLÃivio Reis

#	Article	IF	CITATIONS
19	The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A "Me Too―or "the Special One―Antidiabetic Class?. Journal of Diabetes Research, 2015, 2015, 1-28.	2.3	65
20	Therapeutic and Nutraceutical Potential of Rosmarinic Acid - Cytoprotective Properties and Pharmacokinetic Profile. Critical Reviews in Food Science and Nutrition, 2017, 57, 00-00.	10.3	65
21	Dipeptidyl peptidase-IV inhibition prevents blood–retinal barrier breakdown, inflammation and neuronal cell death in the retina of type 1 diabetic rats. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 1454-1463.	3.8	64
22	Diabetes abrogates sex differences and aggravates cardiometabolic risk in postmenopausal women. Cardiovascular Diabetology, 2013, 12, 61.	6.8	56
23	New Markers of Early Cardiovascular Risk in Multiple Sclerosis Patients: Oxidized-LDL Correlates with Clinical Staging. Disease Markers, 2013, 34, 341-348.	1.3	56
24	Circulating levels of adiponectin, oxidized LDL and C-reactive protein in Portuguese patients with psoriasis vulgaris, according to body mass index, severity and duration of the disease. Journal of Dermatological Science, 2009, 55, 202-204.	1.9	53
25	Gut Microbiota Dysbiosis–Immune Hyperresponse–Inflammation Triad in Coronavirus Disease 2019 (COVID-19): Impact of Pharmacological and Nutraceutical Approaches. Microorganisms, 2020, 8, 1514.	3.6	52
26	Safety profile of solid lipid nanoparticles loaded with rosmarinic acid for oral use: in vitro and animal approaches. International Journal of Nanomedicine, 2016, Volume 11, 3621-3640.	6.7	48
27	Risk Factors for Mortality in Hemodialysis Patients: Two-Year Follow-Up Study. Disease Markers, 2013, 35, 791-798.	1.3	45
28	Inhibition of Bladder Tumor Growth by Chitooligosaccharides in an Experimental Carcinogenesis Model. Marine Drugs, 2012, 10, 2661-2675.	4.6	43
29	Solid Lipid Nanoparticles as Oral Delivery Systems of Phenolic Compounds: Overcoming Pharmacokinetic Limitations for Nutraceutical Applications. Critical Reviews in Food Science and Nutrition, 2015, 57, 00-00.	10.3	43
30	Natural killer cell-based adoptive immunotherapy eradicates and drives differentiation of chemoresistant bladder cancer stem-like cells. BMC Medicine, 2016, 14, 163.	5.5	43
31	Gamma-hydroxybutyric acid endogenous production and post-mortem behaviour – The importance of different biological matrices, cut-off reference values, sample collection and storage conditions. Journal of Clinical Forensic and Legal Medicine, 2014, 27, 17-24.	1.0	42
32	Hepcidin Serum Levels and Resistance to Recombinant Human Erythropoietin Therapy in Haemodialysis Patients. Acta Haematologica, 2009, 122, 226-229.	1.4	41
33	Diet-Induced Rodent Models of Diabetic Peripheral Neuropathy, Retinopathy and Nephropathy. Nutrients, 2020, 12, 250.	4.1	41
34	Exercise training is associated with improved levels of C-reactive protein and adiponectin in ZDF (type) Tj ETQq0 0	0 rgBT /C 1.1	Verlock 107
35	Differential Effects of Acute (Extenuating) and Chronic (Training) Exercise on Inflammation and Oxidative Stress Status in an Animal Model of Type 2 Diabetes Mellitus. Mediators of Inflammation, 2011, 2011, 1-8.	3.0	38

36Glucose and Lipid Dysmetabolism in a Rat Model of Prediabetes Induced by a High-Sucrose Diet.4.138Nutrients, 2017, 9, 638.4.138

FLÃivio Reis

#	Article	IF	CITATIONS
37	Recent Advances and Challenges of mTOR Inhibitors Use in the Treatment of Patients with Tuberous Sclerosis Complex. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-11.	4.0	38
38	New Potential Biomarkers for Chronic Kidney Disease Management—A Review of the Literature. International Journal of Molecular Sciences, 2021, 22, 43.	4.1	38
39	Hypertension Induced by Immunosuppressive Drugs: A Comparative Analysis Between Sirolimus and Cyclosporine. Transplantation Proceedings, 2009, 41, 868-873.	0.6	37
40	Dietâ€induced rodent models of obesityâ€related metabolic disorders—A guide to a translational perspective. Obesity Reviews, 2020, 21, e13081.	6.5	37
41	Reactivation of wild-type and mutant p53 by tryptophanolderived oxazoloisoindolinone SLMP53-1, a novel anticancer small-molecule. Oncotarget, 2016, 7, 4326-4343.	1.8	37
42	Role of Prohepcidin, Inflammatory Markers and Iron Status in Resistance to rhEPO Therapy in Hemodialysis Patients. American Journal of Nephrology, 2008, 28, 677-683.	3.1	36
43	Psoriasis Therapy and Cardiovascular Risk Factors. American Journal of Clinical Dermatology, 2010, 11, 423-432.	6.7	36
44	Therapeutic Use of mTOR Inhibitors in Renal Diseases: Advances, Drawbacks, and Challenges. Oxidative Medicine and Cellular Longevity, 2018, 2018, 1-17.	4.0	36
45	Is Gut Microbiota Dysbiosis a Predictor of Increased Susceptibility to Poor Outcome of COVID-19 Patients? An Update. Microorganisms, 2021, 9, 53.	3.6	36
46	Molecular mechanisms underlying the effects of cyclosporin A and sirolimus on glucose and lipid metabolism in liver, skeletal muscle and adipose tissue in an in vivo rat model. Biochemical Pharmacology, 2014, 88, 216-228.	4.4	35
47	Functional and molecular characterization of cancer stem-like cells in bladder cancer: a potential signature for muscle-invasive tumors. Oncotarget, 2015, 6, 36185-36201.	1.8	34
48	Iron-Hepcidin Dysmetabolism, Anemia and Renal Hypoxia, Inflammation and Fibrosis in the Remnant Kidney Rat Model. PLoS ONE, 2015, 10, e0124048.	2.5	33
49	The incretin system ABCs in obesity and diabetes – novel therapeutic strategies for weight loss and beyond. Obesity Reviews, 2016, 17, 553-572.	6.5	33
50	DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties. Molecular Oncology, 2017, 11, 612-627.	4.6	33
51	Markers of Increased Cardiovascular Risk in Postmenopausal Women: Focus on Oxidized-LDL and HDL Subpopulations. Disease Markers, 2013, 35, 85-96.	1.3	32
52	Lactation as a programming window for metabolic syndrome. European Journal of Clinical Investigation, 2021, 51, e13482.	3.4	32
53	Expression of Genes Encoding Extracellular Matrix Macromolecules and Metalloproteinases in Avian Tibial Dyschondroplasia. Journal of Comparative Pathology, 2011, 145, 174-186.	0.4	28
54	Chemopreventive Efficacy of Atorvastatin against Nitrosamine-Induced Rat Bladder Cancer: Antioxidant, Anti-Proliferative and Anti-Inflammatory Properties. International Journal of Molecular Sciences, 2012, 13, 8482-8499.	4.1	28

#	Article	IF	CITATIONS
55	Obesity and brain inflammation: a focus on multiple sclerosis. Obesity Reviews, 2016, 17, 211-224.	6.5	28
56	lron therapy in chronic kidney disease: Recent changes, benefits and risks. Blood Reviews, 2016, 30, 65-72.	5.7	28
57	Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes. Journal of Diabetes Research, 2017, 2017, 1-14.	2.3	28
58	New markers of early cardiovascular risk in multiple sclerosis patients: oxidized-LDL correlates with clinical staging. Disease Markers, 2013, 34, 341-8.	1.3	27
59	Transition from Cyclosporine-Induced Renal Dysfunction to Nephrotoxicity in an in Vivo Rat Model. International Journal of Molecular Sciences, 2014, 15, 8979-8997.	4.1	26
60	Apoptosis of Peripheral CD4 ⁺ T-Lymphocytes in End-Stage Renal Disease Patients Under Hemodialysis and rhEPO Therapies. Renal Failure, 2011, 33, 138-143.	2.1	25
61	Discovery of a small-molecule protein kinase Cδ-selective activator with promising application in colon cancer therapy. Cell Death and Disease, 2018, 9, 23.	6.3	25
62	Endocannabinoid system in cardiovascular disorders - new pharmacotherapeutic opportunities. Journal of Pharmacy and Bioallied Sciences, 2011, 3, 350.	0.6	24
63	Dichotomous Sirtuins: Implications for Drug Discovery in Neurodegenerative and Cardiometabolic Diseases. Trends in Pharmacological Sciences, 2019, 40, 1021-1039.	8.7	24
64	Sitagliptin prevents aggravation of endocrine and exocrine pancreatic damage in the Zucker Diabetic Fatty rat - focus on amelioration of metabolic profile and tissue cytoprotective properties. Diabetology and Metabolic Syndrome, 2014, 6, 42.	2.7	23
65	The yin and yang faces of the mitochondrial deacetylase sirtuin 3 in age-related disorders. Ageing Research Reviews, 2020, 57, 100983.	10.9	23
66	Extracellular Vesicles and MicroRNA: Putative Role in Diagnosis and Treatment of Diabetic Retinopathy. Antioxidants, 2020, 9, 705.	5.1	23
67	Erythropoietin Promotes Deleterious Cardiovascular Effects and Mortality Risk in a Rat Model of Chronic Sports Doping. Cardiovascular Toxicology, 2009, 9, 201-210.	2.7	22
68	Omega-3 Fatty Acids Inhibit Tumor Growth in a Rat Model of Bladder Cancer. BioMed Research International, 2013, 2013, 1-11.	1.9	22
69	High sucrose consumption induces memory impairment in rats associated with electrophysiological modifications but not with metabolic changes in the hippocampus. Neuroscience, 2016, 315, 196-205.	2.3	22
70	Treadmill running and swimming imposes distinct cardiovascular physiological adaptations in the rat: Focus on serotonergic and sympathetic nervous systems modulation. Acta Physiologica Hungarica, 2008, 95, 365-381.	0.9	21
71	Implication of Low HDL-c Levels in Patients with Average LDL-c Levels: A Focus on Oxidized LDL, Large HDL Subpopulation, and Adiponectin. Mediators of Inflammation, 2013, 2013, 1-12.	3.0	21
72	SLMP53-2 Restores Wild-Type-Like Function to Mutant p53 through Hsp70: Promising Activity in Hepatocellular Carcinoma. Cancers, 2019, 11, 1151.	3.7	21

#	Article	IF	CITATIONS
73	Vitreous humour as a complementary sample to blood for the detection/confirmation of diazepam: ante-mortem and post-mortem studies in an animal model. Human and Experimental Toxicology, 2004, 23, 571-577.	2.2	20
74	A selective p53 activator and anticancer agent to improve colorectal cancer therapy. Cell Reports, 2021, 35, 108982.	6.4	20
75	Anti-inflammatory, anti-proliferative and antioxidant profiles of selective cyclooxygenase-2 inhibition as chemoprevention for rat bladder carcinogenesis. Cancer Biology and Therapy, 2009, 8, 1615-1622.	3.4	19
76	Short and long term in vivo effects of Cyclosporine A and Sirolimus on genes and proteins involved in lipid metabolism in Wistar rats. Metabolism: Clinical and Experimental, 2014, 63, 702-715.	3.4	19
77	Blueberry as an Attractive Functional Fruit to Prevent (Pre)Diabetes Progression. Antioxidants, 2021, 10, 1162.	5.1	19
78	Cardiac antiapoptotic and proproliferative effect of recombinant human erythropoietin in a moderate stage of chronic renal failure in the rat. Journal of Pharmacy and Bioallied Sciences, 2012, 4, 76.	0.6	18
79	Rapamycin negatively impacts insulin signaling, glucose uptake and uncoupling protein-1 in brown adipocytes. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2016, 1861, 1929-1941.	2.4	18
80	Platelet Activation is Increased in Cyclosporin A-Induced Hypertensive Rats. Journal of Cardiovascular Pharmacology, 2000, 36, 56-64.	1.9	16
81	Main Determinants of PON1 Activity in Hemodialysis Patients. American Journal of Nephrology, 2012, 36, 317-323.	3.1	16
82	The Signaling Pathway of TNF Receptors: Linking Animal Models of Renal Disease to Human CKD. International Journal of Molecular Sciences, 2022, 23, 3284.	4.1	16
83	Oxidative Stress in Cyclosporine-Induced Hypertension: Evidence of Beneficial Effects or Tolerance Development With Nitrate Therapy. Transplantation Proceedings, 2007, 39, 2494-2500.	0.6	15
84	Erythroid Disturbances Before and After Treatment of Portuguese Psoriasis Vulgaris Patients. American Journal of Clinical Dermatology, 2012, 13, 37-47.	6.7	15
85	mTOR Signaling in Cardiometabolic Disease, Cancer, and Aging. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-4.	4.0	15
86	The Protective Role of Adiponectin for Lipoproteins in End-Stage Renal Disease Patients: Relationship with Diabetes and Body Mass Index. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-11.	4.0	15
87	Weight loss achieved by bariatric surgery modifies high-density lipoprotein subfractions and low-density lipoprotein oxidation towards atheroprotection. Clinical Biochemistry, 2019, 63, 46-53.	1.9	15
88	Effect of preventive and regressive isosorbide 5-mononitrate treatment on catecholamine levels in plasma, platelets, adrenals, left ventricle and aorta in cyclosporin A-induced hypertensive rats. Life Sciences, 2005, 77, 2514-2528.	4.3	14
89	Inhibition of bladder tumour growth by sirolimus in an experimental carcinogenesis model. BJU International, 2011, 107, 135-143.	2.5	14
90	Effects of Cyclosporine and Sirolimus on Insulin-Stimulated Glucose Transport and Glucose Tolerance in a Rat Model. Transplantation Proceedings, 2013, 45, 1142-1148.	0.6	14

#	Article	IF	CITATIONS
91	Cyclosporine A enhances gluconeogenesis while sirolimus impairs insulin signaling in peripheral tissues after 3 weeks of treatment. Biochemical Pharmacology, 2014, 91, 61-73.	4.4	14
92	The dipeptidyl peptidase 4 inhibitor sitagliptin improves oxidative stress and ameliorates glomerular lesions in a rat model of type 1 diabetes. Life Sciences, 2019, 234, 116738.	4.3	14
93	Development of a Healthy Lifestyle Assessment Toolkit for the General Public. Frontiers in Medicine, 2019, 6, 134.	2.6	14
94	Hepcidin in chronic kidney disease anemia. Vitamins and Hormones, 2019, 110, 243-264.	1.7	14
95	The unsolved cyclosporine-induced kidney injury: is paricalcitol a feasible new renoprotective option?. Kidney International, 2010, 77, 1055-1057.	5.2	13
96	The role of inflammation in diabetic cardiomyopathy. International Journal of Interferon, Cytokine and Mediator Research, 0, , 59.	1.1	13
97	The Peripheral Serotonergic System and Platelet Aggregation in Cyclosporin A-Induced Hypertensive Rats. Thrombosis Research, 1999, 96, 365-372.	1.7	12
98	THE DISTRIBUTION OF CATECHOLAMINES BETWEEN PLASMA AND PLATELETS IN CYCLOSPORIN A-INDUCED HYPERTENSIVE RATS. Pharmacological Research, 2000, 41, 129-135.	7.1	12
99	Potential Cardiovascular Risk Protection of Bilirubin in End-Stage Renal Disease Patients under Hemodialysis. BioMed Research International, 2014, 2014, 1-9.	1.9	12
100	Aging is Associated with Impaired Renal Function, INF-gamma Induced Inflammation and with Alterations in Iron Regulatory Proteins Gene Expression. , 2014, 5, 356-65.		12
101	Cardiovascular effects of cyclosporin treatment in an experimental model. Revista Portuguesa De Cardiologia, 2002, 21, 141-55.	0.5	12
102	Preventive but Not Curative Efficacy of Celecoxib on Bladder Carcinogenesis in a Rat Model. Mediators of Inflammation, 2010, 2010, 1-11.	3.0	11
103	Circulating cell-free DNA levels in hemodialysis patients and its association with inflammation, iron metabolism, and rhEPO doses. Hemodialysis International, 2013, 17, n/a-n/a.	0.9	11
104	Resistance to Recombinant Human Erythropoietin Therapy in a Rat Model of Chronic Kidney Disease Associated Anemia. International Journal of Molecular Sciences, 2016, 17, 28.	4.1	11
105	Pathological and molecular mechanisms underlying resistance to recombinant human erythropoietin therapy in the remnant kidney rat model of chronic kidney disease associated anemia. Biochimie, 2016, 125, 150-162.	2.6	11
106	Subtle thinning of retinal layers without overt vascular and inflammatory alterations in a rat model of prediabetes. Molecular Vision, 2018, 24, 353-366.	1.1	11
107	Recombinant human erythropoietin treatment protects the cardio-renal axis in a model of moderate chronic renal failure. Renal Failure, 2010, 32, 1073-1080.	2.1	10
108	Body mass index and resistance to recombinant human erythropoietin therapy in maintenance hemodialysis patients. Renal Failure, 2013, 35, 1392-1398.	2.1	10

#	Article	IF	CITATIONS
109	Renal riskâ€benefit determinants of recombinant human erythropoietin therapy in the remnant kidney rat model – hypertension, anaemia, inflammation and drug dose. Clinical and Experimental Pharmacology and Physiology, 2016, 43, 343-354.	1.9	10
110	A fast and reliable method for GHB quantitation in whole blood by GC–MS/MS (TQD) for forensic purposes. Journal of Pharmaceutical and Biomedical Analysis, 2016, 119, 139-144.	2.8	10
111	Comparison of endogenous GHB concentrations in blood and hair in death cases with emphasis on the post mortem interval. International Journal of Legal Medicine, 2016, 130, 959-965.	2.2	10
112	Crescent-Like Lesions as an Early Signature of Nephropathy in a Rat Model of Prediabetes Induced by a Hypercaloric Diet. Nutrients, 2020, 12, 881.	4.1	10
113	Blueberry Counteracts Prediabetes in a Hypercaloric Diet-Induced Rat Model and Rescues Hepatic Mitochondrial Bioenergetics. Nutrients, 2021, 13, 4192.	4.1	10
114	Conversion to Sirolimus Ameliorates Cyclosporine-Induced Nephropathy in the Rat: Focus on Serum, Urine, Gene, and Protein Renal Expression Biomarkers. BioMed Research International, 2014, 2014, 1-17.	1.9	9
115	Circadian and seasonal variation of endogenous ubiquinone plasma level. Chronobiology International, 2002, 19, 599-614.	2.0	8
116	lsosorbide-5-mononitrate treatment prevents cyclosporin A-induced platelet hyperactivation and the underlying nitric oxide–cyclic guanosine-3′,5′-monophosphate disturbances. Thrombosis Research, 2003, 110, 107-115.	1.7	8
117	Characterization of a Rat Model of Moderate Chronic Renal Failure—Focus on Hematological, Biochemical, and Cardio-Renal Profiles. Renal Failure, 2009, 31, 833-842.	2.1	8
118	Diabetic encephalopathy: the role of oxidative stress and inflammation in type 2 diabetes. International Journal of Interferon, Cytokine and Mediator Research, 0, , 75.	1.1	8
119	mTOR Signaling in Cardiometabolic Disease, Cancer, and Aging 2018. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-3.	4.0	8
120	1,8-Cineole ameliorates right ventricle dysfunction associated with pulmonary arterial hypertension by restoring connexin43 and mitochondrial homeostasis. Pharmacological Research, 2022, 180, 106151.	7.1	8
121	Liver iron is a major regulator of hepcidin gene expression via <scp>BMP/SMAD</scp> pathway in a rat model of chronic renal failure under treatment with high r <scp>H</scp> u <scp>EPO</scp> doses. BioFactors, 2016, 42, 296-306.	5.4	8
122	Emergent Biomarkers of Residual Cardiovascular Risk in Patients with Low HDL-c and/or High Triglycerides and Average LDL-c Concentrations: Focus on HDL Subpopulations, Oxidized LDL, Adiponectin, and Uric Acid. Scientific World Journal, The, 2013, 2013, 1-16.	2.1	7
123	Inflammatory biomarkers in staging of chronic kidney disease: elevated TNFR2 levels accompanies renal function decline. Inflammation Research, 2022, 71, 591-602.	4.0	7
124	Impairment of vascular and platelet levels of nitric oxide and cyclic guanosine-3',5'-monophosphate in cyclosporin A-induced hypertensive rats. Fundamental and Clinical Pharmacology, 2003, 17, 43-50.	1.9	6
125	Health-related quality of life in Portuguese psoriatic patients: Relation with Psoriasis Area and Severity Index and different types of classical psoriatic treatment. Journal of Dermatology, 2011, 38, 816-819.	1.2	6
126	Serum and Renal Tissue Markers of Nephropathy in Rats Under Immunosuppressive Therapy: Cyclosporine Versus Sirolimus. Transplantation Proceedings, 2013, 45, 1149-1156.	0.6	6

FLÃivio Reis

#	Article	IF	CITATIONS
127	mTOR and Neuroinflammation. , 2016, , 317-329.		6
128	Recombinant human erythropoietin-induced erythropoiesis regulates hepcidin expression over iron status in the rat. Blood Cells, Molecules, and Diseases, 2016, 59, 63-70.	1.4	6
129	Platelet Hyperactivation in Maintained Growth Hormone-Deficient Childhood Patients after Therapy Withdrawal as a Putative Earlier Marker of Increased Cardiovascular Risk. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 98-105.	3.6	5
130	Dual Effect of Nitrate Therapy for Cyclosporine-Induced Hypertension on Vascular and Platelet Morphofunctional Markers; An Animal Model. Transplantation Proceedings, 2007, 39, 2501-2506.	0.6	5
131	Iron as the Key Modulator of Hepcidin Expression in Erythroid Antibody-Mediated Hypoplasia. BioMed Research International, 2014, 2014, 1-10.	1.9	5
132	Cardiorenal benefits of early versus late cyclosporine to sirolimus conversion in a rat model. Journal of Pharmacology and Pharmacotherapeutics, 2012, 3, 143-8.	0.4	5
133	CURATIVE ISOSORBIDE-5-MONONITRATE TREATMENT, IN OPPOSITION TO THE BENEFICIAL PREVENTIVE ONE, ACGRAVATES THE PROTHROMBOTIC AND PROCONSTRICTOR STATE IN CYCLOSPORINE-INDUCED HYPERTENSIVE RATS. Clinical and Experimental Pharmacology and Physiology, 2005, 32, 640-648.	1.9	4
134	DMT1 (NRAMP2/DCT1) Genetic Variability and Resistance to Recombinant Human Erythropoietin Therapy in Chronic Kidney Disease Patients under Haemodialysis. Acta Haematologica, 2008, 120, 11-13.	1.4	4
135	Elastase release during the hemodialysis procedure seems to induce changes in red blood cell membrane proteins. Hemodialysis International, 2011, 15, 429-431.	0.9	4
136	Major Determinants of BMP-2 Serum Levels in Hemodialysis Patients. Renal Failure, 2012, 34, 1355-1358.	2.1	4
137	Impaired renal endothelial nitric oxide synthase and reticulocyte production as modulators of hypertension induced by rHuEPO in the rat. Life Sciences, 2016, 151, 147-156.	4.3	4
138	Blueberry Consumption Challenges Hepatic Mitochondrial Bioenergetics and Elicits Transcriptomics Reprogramming in Healthy Wistar Rats. Pharmaceutics, 2020, 12, 1094.	4.5	4
139	Editorial: Combating Redox Imbalance-Associated Complications With Natural Products. Frontiers in Pharmacology, 2021, 12, 802750.	3.5	4
140	Vascular Access versus the Effect of Statins on Inflammation and Fibrinolysis in Renal Dialysis Patients. Journal of Vascular Access, 2013, 14, 335-341.	0.9	3
141	Influence of the 6-month physical activity programs on renal function in obese boys. Pediatric Research, 2018, 83, 1011-1015.	2.3	3
142	Unhealthy lifestyles, environment, well-being and health capability in rural neighbourhoods: a community-based cross-sectional study. BMC Public Health, 2021, 21, 1628.	2.9	3
143	mTOR in Diabetic Nephropathy and Retinopathy. , 2016, , 379-393.		2
144	Therapeutic strategies targeting oxidative stress to improve dyslipidemia and left ventricular hypertrophy. Revista Portuguesa De Cardiologia, 2017, 36, 639-640.	0.5	2

#	Article	IF	CITATIONS
145	Assessing Scientific Soundness and Translational Value of Animal Studies on DPP4 Inhibitors for Treating Type 2 Diabetes Mellitus. Biology, 2021, 10, 155.	2.8	2
146	Subpopulations of High-Density Lipoprotein: Friends or Foes in Cardiovascular Disease Risk in Chronic Kidney Disease?. Biomedicines, 2021, 9, 554.	3.2	2
147	Are threshold levels of signal transduction required for the protective effect of cilostazol against cardiac ischaemia-reperfusion injury?. Clinical and Experimental Pharmacology and Physiology, 2011, 38, 651-653.	1.9	1
148	rhEPO for the Treatment of Erythropoietin Resistant Anemia in Hemodialysis Patients – Risks and Benefits. , 2013, , .		1
149	Haptoglobin 2–2 phenotype is associated with decreased serum iron levels in endstage renal disease patients resistant to rhEPO therapy. British Journal of Biomedical Science, 2014, 71, 79-81.	1.3	1
150	SP313LIVER IRON IS A MAJOR REGULATOR OF HEPCIDIN GENE EXPRESSION VIA BMP/SMAD PATHWAY IN A RAT MODEL OF CHRONIC RENAL FAILURE UNDER TREATMENT WITH HIGH rHuEPO DOSES. Nephrology Dialysis Transplantation, 2016, 31, i194-i194.	0.7	1
151	Effect of Recombinant Human Erythropoietin in a Rat Model of Moderate Chronic Renal Failure - Focus on Inflammation, Oxidative Stress and Function/Renoprotection. The Open Drug Discovery Journal, 2010, 2, 25-32.	0.7	1
152	Letter to the Editor: A potential mechanism for the pathogenesis of psoriasis <i>vulgaris</i> . International Journal of Dermatology, 2013, 52, 1429-1432.	1.0	0
153	Remyelination in Multiple Sclerosis – How Close are We?. Journal of Neurology & Neurophysiology, 2014, 05, .	0.1	Ο
154	The HIF System Response to ESA Therapy in CKDâ€Anemia. , 2017, , .		0
155	P1581IMPACT OF ACHIEVING LDL CHOLESTEROL LOWER THAN 100 MG/DL WITH STATINS, ON LIPID PROFILE AND INFLAMMATION IN END-STAGE RENAL DISEASE PATIENTS. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	Ο
156	Blueberry effects on prediabetic nephropathy—a preclinical in vivo approach. European Journal of Public Health, 2021, 31, .	0.3	0
157	The impact of refined food processing on the kidney—preclinical evaluation. European Journal of Public Health, 2021, 31, .	0.3	0